Close Menu

NEW YORK (GenomeWeb) — Yikon Genomics said today that it has signed an agreement to launch its noninvasive chromosomal screening assay for aneuploidy with the Center for Reproductive Health & Gynecology (CRHG), a Beverly Hills, California-based in vitro fertilization center.

The test uses next-generation sequencing to screen embryos for chromosomal aneuploidy prior to implantation, according to Shanghai-based Yikon. It analyzes in vitro embryo culture medium and does not require a biopsy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.